Press Releases

2022

Apr 23, 2022

Orasis Pharmaceuticals Announces Phase 2b Trial Efficacy and Safety Results of CSF-1 at the 2022 ASCRS Annual Meeting

Read More

Apr 21, 2022

Orasis Pharmaceuticals Announces Positive Phase 3 Topline Results of Novel Eye Drop Candidate, CSF-1, for the Treatment of Presbyopia

Read More

Apr 11, 2022

Orasis Pharmaceuticals to Present New Data on Novel Presbyopia Candidate at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Read More

Apr 07, 2022

Orasis Pharmaceuticals Appoints Teresa (Tes) Ignacio, M.D. as Vice President, Medical Affairs

Read More

Mar 15, 2022

Orasis Pharmaceuticals Concludes Phase 3 Clinical Trials for Presbyopia Candidate

Read More

2021

Oct 04, 2021

Orasis Pharmaceuticals Appoints Julie Speed as Senior Vice President, Head of Strategy and Marketing to Lead Commercial Growth Plan

Read More

Apr 26, 2021

Orasis Pharmaceuticals Appoints Industry Veteran, Paul Smith, as President and Chief Operating Officer to Lead the Next Phase of Growth

Read More

2020

Oct 28, 2020

Orasis Pharmaceuticals Announces Initiation of Phase 3 Clinical Studies of Novel Eye Drop Candidate for the Treatment of Presbyopia

Read More

Sep 10, 2020

Orasis Raises $30 Million to Advance the Clinical Development of Novel Treatment for Presbyopia

Read More

2019

Oct 10, 2019

Orasis Pharmaceuticals Announces CSF-1 Eye Drop Successfully Met Primary Endpoint in Phase 2b Clinical Study in Presbyopia

Read More